Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer

Research output: Contribution to journalArticleOther

14 Citations (Scopus)

Abstract

Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.
Original languageEnglish
Pages (from-to)305 - 308
Number of pages4
JournalBone
Volume55
Issue number2
DOIs
Publication statusPublished - 2013

Cite this

@article{e8189f0c38374905bb78610247f69129,
title = "Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer",
abstract = "Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.",
author = "Francis Milat and Goh, {Sue Lyn} and Gani, {L U} and C Suriadi and Gillespie, {Matthew T} and Teede, {Helena Jane} and Fuller, {Peter J}",
year = "2013",
doi = "10.1016/j.bone.2013.04.012",
language = "English",
volume = "55",
pages = "305 -- 308",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier",
number = "2",

}

Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. / Milat, Francis; Goh, Sue Lyn; Gani, L U; Suriadi, C; Gillespie, Matthew T; Teede, Helena Jane; Fuller, Peter J.

In: Bone, Vol. 55, No. 2, 2013, p. 305 - 308.

Research output: Contribution to journalArticleOther

TY - JOUR

T1 - Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer

AU - Milat, Francis

AU - Goh, Sue Lyn

AU - Gani, L U

AU - Suriadi, C

AU - Gillespie, Matthew T

AU - Teede, Helena Jane

AU - Fuller, Peter J

PY - 2013

Y1 - 2013

N2 - Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.

AB - Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26 days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23685544

U2 - 10.1016/j.bone.2013.04.012

DO - 10.1016/j.bone.2013.04.012

M3 - Article

VL - 55

SP - 305

EP - 308

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -